Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Protalix BioTherapeutics Q2 EPS $0.21 Beats $(0.04) Estimate, Sales $35.08M Beat $10.22M Estimate

Author: Benzinga Newsdesk | August 07, 2023 06:55am
Protalix BioTherapeutics (AMEX:PLX) reported quarterly earnings of $0.21 per share which beat the analyst consensus estimate of $(0.04) by 625 percent. This is a 290.91 percent increase over losses of $(0.11) per share from the same period last year. The company reported quarterly sales of $35.08 million which beat the analyst consensus estimate of $10.22 million by 243.25 percent. This is a 300.78 percent increase over sales of $8.75 million the same period last year.

Posted In: PLX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist